CSS
ATRA icon

Cubist Systematic Strategies’s Atara Biotherapeutics ATRA Stock Holding History

Cubist Systematic Strategies’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-12,682
Closed -$169K – 2845
2024
Q4 		$169K Buy
+12,682
New +$134K ﹤0.01% 2616
2024
Q3 		– Sell
-9,271
Closed -$78.8K – 2975
2024
Q2 		$78.8K Buy
+9,271
New +$139K ﹤0.01% 2659
2024
Q1 		– Sell
-1,458
Closed -$18.7K – 3699
2023
Q4 		$18.7K Sell
1,458
-320
-18% -$7.46K ﹤0.01% 3357
2023
Q3 		$65.8K Sell
1,778
-9,285
-84% -$413K ﹤0.01% 2997
2023
Q2 		$445K Buy
11,063
+2,889
+35% +$163K ﹤0.01% 2464
2023
Q1 		$593K Buy
8,174
+916
+13% +$88.8K ﹤0.01% 2563
2022
Q4 		$595K Buy
7,258
+6,239
+612% +$650K ﹤0.01% 2899
2022
Q3 		$96K Sell
1,019
-9
-0.9% -$1.01K ﹤0.01% 4027
2022
Q2 		$200K Sell
1,028
-1,778
-63% -$290K ﹤0.01% 3702
2022
Q1 		$652K Buy
2,806
+2,053
+273% +$654K 0.01% 2367
2021
Q4 		$297K Buy
753
+51
+7% +$21.5K ﹤0.01% 2805
2021
Q3 		$314K Sell
702
-792
-53% -$284K ﹤0.01% 2328
2021
Q2 		$581K Sell
1,494
-2,644
-64% -$943K 0.01% 1909
2021
Q1 		$1.49M Buy
4,138
+1,841
+80% +$814K 0.02% 1256
2020
Q4 		$1.13M Buy
2,297
+1,780
+344% +$822K 0.02% 1310
2020
Q3 		$167K Buy
517
+260
+101% +$88.5K ﹤0.01% 2178
2020
Q2 		$94K Sell
257
-1,301
-84% -$329K ﹤0.01% 2203
2020
Q1 		$331K Buy
+1,558
New +$494K 0.01% 1465
2019
Q4 		– Sell
-2,510
Closed -$886K – 2408
2019
Q3 		$886K Buy
2,510
+695
+38% +$259K 0.02% 1033
2019
Q2 		$912K Buy
+1,815
New +$1.28M 0.02% 1100
2019
Q1 		– Sell
-53
Closed -$46K – 2238
2018
Q4 		$46K Buy
+53
New +$49.2K ﹤0.01% 1878
2015
Q2 		– Sell
-69
Closed -$71K – 1817
2015
Q1 		$71K Sell
69
-345
-83% -$228K ﹤0.01% 1711
2014
Q4 		$277K Buy
+414
New +$253K 0.02% 1279

Other funds holding ATRA

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.57B AUM 26.96% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cubist Systematic Strategies's ATRA Position: Q1 2025 in Review

Cubist Systematic Strategies sold out of Atara Biotherapeutics (ATRA) in Q1 2025, closing a stake of 12,682 shares — an estimated $169K sold.

Cubist Systematic Strategies first reported a position in ATRA in Q4 2014 and held it in 23 quarters. The position peaked at $1.49M in Q1 2021. 37 funds tracked by Wall St. Rank hold ATRA as of Q1 2025.

  • Cubist Systematic Strategies reported no remaining Atara Biotherapeutics position as of Q1 2025 after selling out during the quarter.
  • Cubist Systematic Strategies sold 12,682 Atara Biotherapeutics shares in Q1 2025, an estimated $169K.
  • Cubist Systematic Strategies first reported a position in Atara Biotherapeutics in Q4 2014 and held it in 23 quarters.
  • Cubist Systematic Strategies's Atara Biotherapeutics position peaked at $1.49M in Q1 2021.
  • 37 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2025.

Based on Cubist Systematic Strategies's 13F filing for Q1 2025, filed 15 May 2025.